Purpose To provide a detailed account of the discussions, decisions, and presentations from the All-Party Parliamentary Group (APPG) meeting on Myalgic Encephalomyelitis (ME). Key Points Re-Election of Officers Dr. Des Turner MP was re-elected as Chair, supported by other existing officers. Presentation on NHS Services Dr. Terry Mitchell, clinical champion for ME/CFS in East Anglia,…
Purpose To provide an overview of recent developments in government initiatives and research efforts aimed at improving care, support, and understanding of ME/CFS. Key Points Consultation Feedback Analysis of responses to the interim delivery plan, “My Full Reality,” emphasized the need for enhanced healthcare services and increased research funding. Parliamentary Engagement Discussions and written questions…
Purpose: To detail a model for enabling severely affected Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) patients to actively participate in research, overcoming traditional barriers and ensuring their experiences are represented. Key Points: Challenges in Participation: Severely affected ME/CFS patients are often excluded from research due to physical and cognitive limitations, sensory sensitivities, and a lack of…
Purpose: To provide a research model enabling very severely affected Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) patients to participate in studies, addressing their unique challenges and ensuring their voices are heard. Key Points: Challenges in Research Participation: Historically, very severely affected ME/CFS patients have been excluded from studies due to their condition being described as “hard…
Purpose: To highlight the nutritional challenges faced by patients with very severe Myalgic Encephalomyelitis (ME/CFS), emphasizing the need for timely medical intervention and raising awareness among healthcare professionals. Key Points: Causes of Nutritional Challenges: Severe debilitation making eating and drinking exhausting. Dysphagia (difficulty swallowing), gastroparesis, malabsorption, and Mast Cell Activation Disorder (MCAD). Lack of recognition…
Purpose: To highlight the unique challenges faced by children with Severe Myalgic Encephalomyelitis (ME), emphasizing the need for accurate diagnosis, compassionate care, and tailored management strategies. Key Points: Definition and Severity: Severe ME affects children who are housebound or bedbound, functioning at 5–15% of normal capacity. Very Severe ME involves continuous debilitating symptoms, with patients…
Purpose: To evaluate the impact of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) on work capacity, prognosis, and the effectiveness of rehabilitation and medical retirement strategies. Key Points: Overview of ME/CFS: ME/CFS is a severe neurological disease characterized by post-exertional malaise (PEM) and significant quality-of-life disruption. Common symptoms include muscle weakness, cognitive dysfunction, sleep disturbances, and chronic…
Purpose: To provide essential advice and best practices for treating Myalgic Encephalomyelitis (ME) patients in hospital settings, addressing their unique needs and sensitivities to improve outcomes. Key Points: Hospital Environment Challenges: Noise, light, and sensory overload worsen symptoms; private rooms and quiet spaces are necessary. Sleep disruption due to hypersensitivity requires careful consideration to avoid…
Purpose: To introduce Nimodipine, a calcium channel blocker, as a potential treatment for Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (ME/CFS), highlighting its benefits, mechanisms, and usage protocols. Key Points: Potential Benefits: Improves mental clarity, alertness, energy levels, and stamina. Reduces fatigue, muscle pain, and headaches for some patients. Approximately half of users report noticeable improvement with minimal…
Purpose: To provide an in-depth exploration of the potential benefits, mechanisms, and practical considerations of using Nimodipine, a calcium channel blocker, for managing Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). Key Points: Drug Overview: Nimodipine is a second-generation L-type calcium channel blocker, primarily used to improve blood flow in the brain by relaxing blood vessel walls. It…